- 全部删除
 
您的购物车当前为空
Sotagliflozin (LP-802034) 是有效的SGLT1/2抑制剂,用作抗糖尿病剂。


为众多的药物研发团队赋能,
让新药发现更简单!
Sotagliflozin (LP-802034) 是有效的SGLT1/2抑制剂,用作抗糖尿病剂。
| 规格 | 价格 | 库存 | 数量 | 
|---|---|---|---|
| 1 mg | ¥ 315  | In stock | |
| 2 mg | ¥ 447  | In stock | |
| 5 mg | ¥ 861  | In stock | |
| 10 mg | ¥ 1,420  | In stock | |
| 25 mg | ¥ 2,870  | In stock | |
| 50 mg | ¥ 4,260  | In stock | |
| 100 mg | ¥ 5,950  | In stock | |
| 500 mg | ¥ 12,300  | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 853  | In stock | 
Sotagliflozin 相关产品
| 产品描述 | Sotagliflozin (LP-802034) is an orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity.  | 
| 靶点活性 |  SGLT2:0.6 nM (mouse), SGLT1:36 nM (human), SGLT1:62 nM (mouse), SGLT2:1.8 nM (human)  | 
| 体外活性 | LX4211 在小鼠体内抑制[14C]AMG的吸收,其对小鼠SGLT1的IC50为62.0 nM,对小鼠SGLT2的IC50则为0.6 nM。[2]  | 
| 体内活性 | 在小鼠中,LX4211 (60 mg/kg, p.o.) 通过抑制SGLT1减少肠道葡萄糖吸收,从而总体上增加GLP-1和PYY的释放,并降低GIP的释放和血糖波动。[2] 在非肥胖型1糖尿病倾向的小鼠中,Sotagliflozin (30 mg/kg) 显著改善了血糖控制,而不增加低血糖测量的频率。[3]  | 
| 别名 | LX-4211, LP-802034 | 
| 分子量 | 424.94 | 
| 分子式 | C21H25ClO5S | 
| CAS No. | 1018899-04-1 | 
| Smiles | CCOc1ccc(Cc2cc(ccc2Cl)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)cc1 | 
| 密度 | 1.37 g/cm3 (Predicted) | 
| 存储 | keep away from moisture,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 262.5 mg/mL (617.73 mM), Sonication is recommended.  H2O: < 1 mg/mL (insoluble or slightly soluble)  Ethanol: 14 mg/mL (32.95 mM), Sonication is recommended.   | ||||||||||||||||||||||||||||||||||||||||
溶液配制表  | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO 
 DMSO 
  | |||||||||||||||||||||||||||||||||||||||||
评论内容